Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Klinisk randomiseret fase 2-forsøg med AP31969 versus placebo til rytmekontrol af atrieflimren (END-AF-1)

28. september 2026 opdateret af: Acesion Pharma

Klinisk randomiseret fase 2-forsøg af AP31969 versus placebo til rytmekontrol af atrieflimren

A clinical Randomized Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The key goal of this clinical trial is to assess the effectiveness of different doses of AP31969 in lowering Atrial Fibrillation (AF) burden and its safety.

Participants will be randomly assigned to one of the following groups:

  • AP31969 at 100 mg, 200 mg, or 350 mg doses
  • AP31969 500 mg (not included at the trial start)
  • Placebo (inactive treatment and has no active properties). The placebo group serves as the comparator for AP31969. All treatments are given orally, twice daily.

The trial includes 3 periods: screening (up to 4 weeks), treatment (12 weeks), and follow-up (30 days). The duration of the trial for a participant is approximately 20 weeks.

Participants will receive an implantable loop recorder and undergo assessments during the visits at specific times, for example blood and urine analyses, and electrocardiogram.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

200

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • PD
      • Plovdiv, PD, Bulgarien, 4002
        • Rekruttering
        • UMHAT "Sveti Georgi" EAD, Department of Invasive Cardiology
    • SOF
      • Sofia, SOF, Bulgarien, 1000
        • Rekruttering
        • Acibadem City Clinic, Cardiology Department
      • Sofia, SOF, Bulgarien, 1365
        • Trukket tilbage
        • MHAT National Cardiology Hospital EAD, Cardiology Department
      • Sofia, SOF, Bulgarien, 1431
        • Rekruttering
        • Aleksandrovska University Hospital, Clinic of Cardiology
    • VAR
      • Varna, VAR, Bulgarien, 9000
        • Rekruttering
        • SHATC Cardiolife, Invasive Cardiology
      • Varna, VAR, Bulgarien, 9020
        • Rekruttering
        • Medical Center Nova Clinic
      • Hellerup, Danmark, 2730
        • Rekruttering
        • University Hospital Herlev and Gentofte Department of Cardiology
      • Viborg, Danmark, 8800
        • Rekruttering
        • Viborg Hospital, Department of Cardiology
      • Arnhem, Holland, 6815 AD
        • Rekruttering
        • Rijnstate Ziekenhuis, Cardiology Department
      • Deventer, Holland, 7416 SE
        • Rekruttering
        • Deventer Ziekenhuis, Cardiology Department
      • Groningen, Holland, 9728 NT
        • Rekruttering
        • Martini Hospital Groningen, Cardiology Department
      • Haarlem, Holland, 2035 RC
        • Rekruttering
        • Spaarne Gasthuis, Cardiology Department
      • Leeuwarden, Holland, 8934 AD
        • Trukket tilbage
        • Frisius MC Leeuwarden, Hart- en Vaatcentrum
      • Maastricht, Holland, 6229 HX
        • Aktiv, ikke rekrutterende
        • Maastricht University Medical Center, Cardiology Department
      • The Hague, Holland, 2545 AA
        • Rekruttering
        • HagaZiekenhuis, Cardiology/Electrophysiology Unit
      • Tiel, Holland, 4002 WP
        • Rekruttering
        • Rivierenland Hospital, Cardiology Department
      • Veldhoven, Holland, 5504 DB
        • Rekruttering
        • Máxima Medisch Centrum, Cardiology Department
      • Milan, Italien, 20162
        • Rekruttering
        • ASST Grande Ospedale Metropolitano Niguarda Cardiology 3 - Electrophysiology "De Gasperis" Cardio Center
      • Milan, Italien, 20122
        • Ikke rekrutterer endnu
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Cardio - Thoracic- Vascular Diseases,
      • Modena, Italien, 30174
        • Rekruttering
        • University of Modena and Reggio Emilia, Policlinico di Modena, Cardiology Department
    • BO
      • Bologna, BO, Italien, 40138
        • Rekruttering
        • Policlinico Sant'Orsola Cardiology Department
    • FE
      • Cona, FE, Italien, 444124
        • Rekruttering
        • Arcispedale Sant'Anna, Cardiology Department
    • VE
      • Mestre, VE, Italien, 30174
        • Rekruttering
        • Dell'Angelo Hospital, Cardiology Department
      • Bydgoszcz, Polen, 85-231
        • Rekruttering
        • Centrum Medyczne KERmed Cardiology Department
      • Chrzanów, Polen, 85-231
        • Rekruttering
        • Małopolskie Centrum Sercowo-Naczyniowe PAKS Oddział Intensywnej Opieki Kardiologicznej
      • Dąbrowa Górnicza, Polen, 41-300
        • Rekruttering
        • Polsko-Amerykańskie Kliniki Serca III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
      • Katowice, Polen, 40-635
        • Ikke rekrutterer endnu
        • Upper-Silesian Medical Center 2nd Department of Cardiology
      • Katowice, Polen, 40-635
        • Ikke rekrutterer endnu
        • Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego w Katowicach
      • Szczecin, Polen, 70-419
        • Rekruttering
        • One Day Med Sp. z o.o. Clinical Trials Department
      • Tychy, Polen, 43-100
        • Rekruttering
        • Polsko-Amerykańskie Kliniki Serca X Oddział Kardiologii Inwazyjnej, Elektrofizjologii i Elektrostymulacji w Tychach im
      • Belgrade, Serbien
        • Rekruttering
        • University Clinical Centre of Serbia Department for Intensive Care in Arrhythmology
      • Belgrade, Serbien
        • Rekruttering
        • Institute for Cardiovascular Disease "Dedinje" Department for Electrophysiology
      • Kamenitz, Serbien
        • Rekruttering
        • Institute for Cardiovascular Diseases Vojvodina Department of Interventional Electrophysiology
      • Kragujevac, Serbien
        • Rekruttering
        • University Clinical Center Kragujevac Clinic of Cardiology (Depar. Electrophysiology)
      • Niš, Serbien
        • Rekruttering
        • University Clinical Center Nis Clinic for Cardiovascular Diseases Bulevar
      • Užice, Serbien, 33100
        • Rekruttering
        • Health Center Uzice Cardiology Department
      • Coburg, Tyskland, 96450
        • Rekruttering
        • Sana Kliniken Oberfranken, Klinikum Coburg Kardiologie und Innere Medizin
      • Frankfurt, Tyskland, 60590
        • Rekruttering
        • Universitätsklinikum Frankfurt Medizinische Klinik III - Kardiologie, Angiologie, Hämostaseologie, Nephrologie
      • Hamburg, Tyskland, 20246
        • Rekruttering
        • Universitaets Klinikum Hamburg-Eppendorf (UKE Hamburg), Kardiologie
      • Budapest, Ungarn, 1122
        • Rekruttering
        • Semmelweis Egyetem Városmajori Sziv- és Érsebészeti Klinika
      • Budapest, Ungarn, 1023
        • Rekruttering
        • Budai Irgalmasrendi Kórház
      • Sopron, Ungarn, 9400
        • Trukket tilbage
        • Soproni Gyógyközpont Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet
      • Szeged, Ungarn, 6725
        • Rekruttering
        • Szent-Györgyi Albert Klinikai Központ, Belgyógyászati Klinika
      • Szolnok, Ungarn, 5000
        • Rekruttering
        • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Rendelőintézet
      • Zalaegerszeg, Ungarn, 8900
        • Rekruttering
        • Belvárosi Egészségház, Platán Magánklinika
    • Hungary
      • Pécs, Hungary, Ungarn, 7622
        • Ikke rekrutterer endnu
        • Pécsi Tudományegyetem Szivgyógyászati Klinika (Cardiology Clinic, University of Pecs)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Willing and able to provide written informed consent.

  • Age 18 or older.

  • ECG documented diagnosis of paroxysmal or persistent AF.

  • AF history at screening indicating an expected AF burden of 1-90%, i.e., at least 1 self-terminating AF episode within 4 months prior to the screening visit.

  • AF burden of ≥ 1% and ≤ 90% assessed with an ECG patch device during the screening period prior to the randomisation visit.

  • Investigator and participant agreement to avoid non-trial related rhythm control intervention for the duration of the trial, including:

    • Antiarrhythmic drug class I and/or III (including amiodarone)
    • Electrical or pharmacological cardioversion
    • AF ablation procedure
  • Willing to have a loop recorder implanted.

Exclusion Criteria:

  • Prior AF ablation procedure other than pulmonary vein isolation (PVI) only.
  • Any of the following events within 4 weeks prior to the screening visit: Myocardial infarction, Unstable angina pectoris, Stroke or transient, ischaemic attack, Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG), Peripheral revascularisation procedure.
  • Cardiac pacing device e.g. pacemaker and cardiac resynchronization therapy device with atrial or ventricular pacing for > 5% of the time or existing implantable loop recorder.
  • Heart failure, New York Heart Association class III (3) or IV (4).
  • Left ventricular ejection fraction < 40% based on imaging (e.g. echocardiography) performed within 6 months prior to or during the screening visit.
  • Clinically significant valvular heart disease, including severe aortic stenosis, severe mitral regurgitation and/or severe mitral stenosis, in the opinion of the investigator.
  • QTc (Fridericia, QTcF) interval > 450 ms for males and > 470 ms for females at screening.
  • eGFR <60 mL/min /1.73 m² based on creatine and CKD-EPI formula
  • Use of antiarrhythmic drug class I and/or III within 7 days or, for amiodarone, within 3 months prior to the screening visit.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: AP31969 100 mg

Tablets, Twice daily, 12 Weeks

Tablets, Oral, Twice daily.

Eksperimentel: AP31969 200 mg

Tablets, Twice daily, 12 Weeks

Tablets, Oral, Twice daily.

Eksperimentel: AP31969 350 mg

Tablets, Twice daily, 12 Weeks

Tablets, Oral, Twice daily.

Eksperimentel: AP31969 500 mg

Tablets, Twice daily, 12 Weeks

Tablets, Oral, Twice daily.

Placebo komparator: Placebo

Tablets, Twice daily, 12 Weeks

Tablets, oral, Twice daily.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Atrial fibrillation burden
Tidsramme: From week 2 to week 12

Measured through implantable loop recorder. Calculated as the amount of time with AF relative to the amount of time the participant is under observation (expressed as a %).

From week 2 to week 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of atrial fibrillation episodes
Tidsramme: From week 2 to week 12

Measured through implantable loop recorder.

From week 2 to week 12
Change from baseline in Atrial Fibrillation Effect on Quality-of-Life
Tidsramme: Week 12

Patient reported outcome. Reporting on a scale of 1 to 7, where 7 is the worse outcome.

Week 12
Number of ventricular tachycardia episodes > 30 seconds of duration
Tidsramme: From week 0 to week 12

Measured through implantable loop recorder.

From week 0 to week 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. oktober 2025

Primær færdiggørelse (Anslået)

1. maj 2027

Studieafslutning (Anslået)

1. juni 2027

Datoer for studieregistrering

Først indsendt

25. november 2025

Først indsendt, der opfyldte QC-kriterier

25. november 2025

Først opslået (Faktiske)

5. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • AP31969-M201
  • 2025-521377-14-00 (Ctis)
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified external researchers may request access to anonymized data and needed trial documentation. Requests are evaluated on the basis of scientific merit. Any use of and access to the data must respect the privacy of the participants and will only be provided if applicable laws and regulations allow this.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner